Fed. Circ. Axes Sanofi IP Claims Over Genentech Cancer Drugs

Law360, New York (March 22, 2012, 4:22 PM EDT) -- The Federal Circuit on Thursday upheld a lower court’s ruling that Genentech Inc. did not infringe Sanofi-Aventis Deutschland GmbH’s patents pertaining to cancer drugs Rituxan and Avastin, rejecting Sanofi’s contentions that the court misconstrued the patents’ language.

A three-judge panel affirmed the California federal court’s ruling that Genentech and biotechnology company Biogen IDEC Inc.’s antibodies used to treat non-Hodgkin's lymphoma, leukemia, arthritis and certain other types of cancer do not infringe U.S. Patent Numbers 5,849,522 and 6,218,140, which pertain to a DNA sequence of the human...
To view the full article, register now.